WP
MLTX icon

Woodline Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Woodline Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49,168
Closed -$648K – 1113
2025
Q4 		$648K Sell
49,168
-11,686
-19% -$138K ﹤0.01% 879
2025
Q3 		$436K Sell
60,854
-249,748
-80% -$13M ﹤0.01% 844
2025
Q2 		$14.7M Buy
310,602
+14,454
+5% +$589K 0.08% 353
2025
Q1 		$11.6M Buy
296,148
+2,613
+0.9% +$113K 0.08% 332
2024
Q4 		$15.9M Buy
293,535
+61,105
+26% +$3.12M 0.11% 251
2024
Q3 		$11.7M Buy
232,430
+5,713
+3% +$268K 0.1% 271
2024
Q2 		$9.97M Buy
226,717
+19,302
+9% +$818K 0.1% 247
2024
Q1 		$10.4M Buy
207,415
+85,661
+70% +$4.65M 0.1% 263
2023
Q4 		$7.35M Buy
121,754
+20,005
+20% +$1.03M 0.08% 264
2023
Q3 		$5.8M Buy
101,749
+52,270
+106% +$2.89M 0.07% 299
2023
Q2 		$2.52M Buy
+49,479
New +$1.33M 0.03% 399

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners's MLTX Position: Q1 2026 in Review

Woodline Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 49,168 shares — an estimated $648K sold.

Woodline Partners first reported a position in MLTX in Q2 2023 and held it in 11 quarters. The position peaked at $15.9M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Woodline Partners reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 49,168 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $648K.
  • Woodline Partners first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 11 quarters.
  • Woodline Partners's MoonLake Immunotherapeutics position peaked at $15.9M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.